The potential mechanism of chemosensitive difference between 2 types of ovarian cancer

Saudi Medical Journal

Volumn 28, Issue 7, 2007, Pages 1044-1049

  He, Xiang ^a   Lin, Bo ^a   Kong, Lei ^a   Zhang, Jiawen ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; VINCRISTINE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT OVARY EPITHELIAL TUMOR; MICROARRAY ANALYSIS; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVARY GERM CELL TUMOR; PROTEIN EXPRESSION; PROTEIN FUNCTION; ADOLESCENT; CARCINOMA; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PROTO ONCOGENE;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CARCINOMA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548415345     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lijuan L, editor. Lin qiaozhi Gynecologic Oncology. 3rd ed. Peking: People's Medical Publishing House; 2000. p.403-593.
2. Shackney SE, McCormack GW, Cuchural GJ Jr. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: An analytical review. Ann Intern Med 1978; 89: 107-121.
3. Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 1989; 28: 113-121.
4. Tubiana M, Malaise E. Comparison of cell proliferation kinetics in human and experimental tumors: Response to irradiation. Cancer Treat Rep 1976; 60: 1887-1895.
5. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. Am J Roentgenol Radium Ther Nucl Med 1956; 76: 988-1000.
6. Anelli A, Brentani RR, Gadelha AP, Amorim De Albuquerque A, Soares F. Correlation of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage IIIB breast cancer. Annals of Oncology 2003; 14: 428-432.
7. Mano Y, Kikuchi Y, Yamamoto K, Kita T, Hirata J, Tode T, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. European Journal of Cancer 1999; 35: 1214-1219.
8. Koshiyama M, Fujii H, Kinezaki M, Yoshida M. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas. Anticancer Research 2001; 21: 905-910.
9. Zhiwei D, Xianzhi G, editors. Clinic Oncology. 1st ed. Peking: People's Medical Publishing House; 2002. p. 266-268.
10. Rubin P, Williams JP. Clinical Oncology. 8th ed. Peking: Health Science Asia; 2002. p. 153-156.
11. Tanmu Z, editor. Antitumor Drug Pharmacology and Clinic Therapy. 1st ed. Zhengzhou: Henan Medical University Press;1999. p. 25-31.
12. Guoqing P, Yu Z, Hua Y. An Analysis on Treatment and Prognosis of 40 Patients with Palindromic Ovarian Carcinoma. Journal of Chinese Physician 2004; 6: 932-933.
13. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol 2004; 498: 1-8.
14. Stumm S, Meyer A, Lindner M, Bastert G, Wallwiener D, Guckel B. Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 2004; 66: 101-111.
15. Guarneri V, Bengala C, Orlandini C, Gennari A, Donati S, Campani D, et al. HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support. Bone Marrow Transplantationm 2004; 34: 13-17.
16. Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, et al. Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. J Clin Oncol 2003; 21: 1320-1325.
17. Warmann S, Gohring G, Teichmann B, Geerlings H, Pietsch T, Fuchs J. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2003; 23: 4607-4611.
18. Vogt U, Falkiewicz B, Bielawski K, Bosse U, Schlotter CM. Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay. Acta Biochim Pol 2000; 47: 157-164.
19. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/ PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000; 19: 5406-5412.
20. Zhaoyou T, editor. Contemporary Oncology. 2nd ed. Shanghai: Fudan University Press; 2000. p. 98-121.
21. Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, et al. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999; 86: 1307-1313.
22. Wu Q, Kreienberg R, Runnebaum IB. Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J Cancer Res Clin Oncol 2000; 126: 139-144.
23. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178-2184.
24. Gao G, Peng Z, Wang H. P53 protein expression in malignant germ cell tumor of ovary and its relationship with clinical course and prognosis. Journal of West China University of Medical Sciences 1997; 28: 420-423.
25. Wu GS, El-Deiry WS. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996; 2: 623-633.
26. MacGrogan G, Rudolph P, Mascarel IDI, Mauriac L, Durand M, Avril A, et al. DNA topoisomerase II alpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 2003; 89: 666-671.
27. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachow J, Karpinska G, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003; 88: 848-854.